171 related articles for article (PubMed ID: 38308184)
1. CSN6-SPOP-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation.
Li K; Zhang J; Lyu H; Yang J; Wei W; Wang Y; Luo H; Zhang Y; Jiang X; Yi H; Wang M; Zhang C; Wu K; Xiao L; Wen W; Xu H; Li G; Wan Y; Yang F; Yang R; Fu X; Qin B; Zhou Z; Zhang H; Lee MH
Adv Sci (Weinh); 2024 Apr; 11(14):e2306827. PubMed ID: 38308184
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides suppress hepatocellular carcinoma cells by blocking cholesterol biosynthesis through inhibition of MVA pathway enzyme HMGCS1.
Xiao MY; Li FF; Xie P; Qi YS; Xie JB; Pei WJ; Luo HT; Guo M; Gu YL; Piao XL
Chem Biol Interact; 2023 Sep; 383():110674. PubMed ID: 37604220
[TBL] [Abstract][Full Text] [Related]
3. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.
Ji P; Liang S; Li P; Xie C; Li J; Zhang K; Zheng X; Feng M; Li Q; Jiao H; Chi X; Zhao W; Zhang S; Wang X
Biochem Biophys Res Commun; 2018 Jul; 502(1):30-42. PubMed ID: 29777712
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CSN6 promotes the epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.
Xu M; Zhen L; Lin L; Wu K; Wang Y; Cai X
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):340-348. PubMed ID: 31422034
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
[TBL] [Abstract][Full Text] [Related]
6. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
7. Compartmentalized activities of HMGCS1 control cervical cancer radiosensitivity.
Zhang X; Sun C; Wan J; Zhang X; Jia Y; Zhou C
Cell Signal; 2023 Jan; 101():110507. PubMed ID: 36328117
[TBL] [Abstract][Full Text] [Related]
8. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
9. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
10. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma.
Zhou P; Chang WY; Gong DA; Huang LY; Liu R; Liu Y; Xia J; Wang K; Tang N; Huang AL
Oncogene; 2023 Mar; 42(10):725-736. PubMed ID: 36604567
[TBL] [Abstract][Full Text] [Related]
12. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
13. circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway.
Zhang S; Ma J; Yu T; Song Z; Lau WY; Zha Y
J Cell Mol Med; 2024 Mar; 28(6):e18137. PubMed ID: 38445791
[TBL] [Abstract][Full Text] [Related]
14. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
Walsh CA; Akrap N; Garre E; Magnusson Y; Harrison H; Andersson D; Jonasson E; Rafnsdottir S; Choudhry H; Buffa F; Ragoussis J; Ståhlberg A; Harris A; Landberg G
PLoS One; 2020; 15(7):e0236187. PubMed ID: 32692762
[TBL] [Abstract][Full Text] [Related]
15. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Sun T; Mao W; Peng H; Wang Q; Jiao L
Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
[TBL] [Abstract][Full Text] [Related]
16. The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma.
Zhang J; Jiang M; Qian L; Lin X; Song W; Gao Y; Zhou Y
Mol Oncol; 2020 Sep; 14(9):2313-2331. PubMed ID: 32491253
[TBL] [Abstract][Full Text] [Related]
17. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
[TBL] [Abstract][Full Text] [Related]
18. Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.
Huang Y; Tan N; Jia D; Jing Y; Wang Q; Li Z; Zhang J; Liu L; Li J; Chen Z; He X
Tumour Biol; 2015 Dec; 36(12):9753-61. PubMed ID: 26156804
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
[TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma.
Guo Y; Peng Q; Hao L; Ji J; Zhang Z; Xue Y; Liu Y; Gao Y; Li C; Shi X
FASEB J; 2022 Jun; 36(6):e22361. PubMed ID: 35616366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
